Kardigan Reports Q3 2026 Financial Results & Business Updates
Health
Earnings
IPO:
Jun 18, 2026
Industry:
PHARMACEUTICAL PREPARATIONS
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates
SOUTH SAN FRANCISCO, Calif., and PRINCETON, N.J., Nov 12, 2026 - Kardigan, Inc. (Nasdaq: KARD), a precision cardiovascular company, reported its financial results for the third quarter ended September 30, 2026, and provided recent business updates across its clinical pipeline.
... Read on — Members only
About Kardigan, Inc.
Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Our mission is to develop multiple targeted cardiovascular treatments in parallel that bring people with cardiovascular diseases closer to the cures they deserve. We leverage deep domain expertise in cardiovascular biology, patient data, and advanced analytics to accelerate drug discovery and development, aiming to deliver impactful therapies efficiently and at scale.
